![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Healthcare Ent. | LSE:HCEG | London | Ordinary Share | GB00B6030H73 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMHCEG RNS Number : 7252V Healthcare Enterprise Group PLC 15 July 2009 Healthcare Enterprise Group plc ("HCEG", "the Company" or "the Group") RESULT OF AGM The Board of Healthcare Enterprise Group plc, a business engaged in the medical product and disinfectant markets, is pleased to announce that all of the Resolutions proposed at the Company's Annual General Meeting ("AGM") held today were duly voted and passed. Accordingly, and pursuant to the announcement released on 19 June 2009, the reorganisation of the Company's existing share capital on the basis that every 250 existing ordinary shares of 0.1 pence be consolidated into one new ordinary share of 25 pence ("New Ordinary Shares") will take effect on 21 July 2009 in accordance with the Circular sent to shareholders. Further, the approval of the capitalisation of its existing indebtedness by the issue of new ordinary shares and the transfer by HCEG of some of its shares in certain subsidiaries was also approved. Application has, therefore, been made to AIM for the admittance of a total of 4,392,126 new ordinary shares of 25 pence each; the trading of such shares is expected to commence at 8:00 a.m. on 21 July 2009. The ISIN for the new consolidated and capitalisation shares is GB00B6030H73. The Circular summarising the Proposals is available on the Company's website at www.hcegroup.com Commenting on the Company's recently approved corporate actions, Lyndon Gaborit, Executive Deputy Chairman said: "These actions have released the Company from significant indebtedness totalling GBP3.26 million and has reduced the Company's obligation to provide all the funding for the development and roll out of the two main underlying businesses. Whilst the Company will retain a significant shareholding in both Ebiox and Reproductive Sciences, the approved actions has the added benefit of allowing those businesses to flourish with additional investment from other shareholders, whilst allowing the Company to choose whether or not to participate in part or in full in future financing. We are very pleased with the progress in the Ebiox business under the stewardship of John Honey, which has attracted new customers and is negotiating the distribution of additional products to meet the upsurge in demand caused by the swine flu pandemic. Significant progress is also being made with Reproductive Sciences which is currently undergoing approvals for its Fertiligent "Evie" pregnancy aid device from the US Food & Drug Administration. The Company will now be actively seeking additional investments in the healthcare and wellness markets. The Company intends to act as a consolidator of smaller quoted and unquoted companies in that sector. With its established shareholder base, access to institutional and private funding and its experienced management team, the Directors believe that the Company is well placed to expand by acquiring smaller businesses which have good products or services but which lack the critical mass to gain significant market entry. The creation of a larger listed entity will allow entrepreneurs and business managers the opportunity to combine with a larger entity to provide both diversification of risk and economies of scale." Further enquiries: Healthcare Enterprise Group plc Lyndon Gaborit, Executive Deputy Chairman Gron Ffoulkes-Davies, Chief Financial Officer Tel: + 44 (0) 1925 898 201 Daniel Stewart & Company plc Graham Webster/Stewart Dick Tel: + 44 (0) 20 7776 6550 Notes to Editor: Healthcare Enterprise Group plc companies include Ebiox Limited, a specialist disinfectant and decontamination company which has a range of proprietary products patented and approved for sale in multiple world markets; Reproductive Sciences Limited which invests in medical devices product development, particularly in the area of women's health; and investments in healthcare products and services. This information is provided by RNS The company news service from the London Stock Exchange END RAGSFAFDISUSESW
1 Year Healthcare Enterprise Chart |
1 Month Healthcare Enterprise Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions